ZA200309122B - Identifying parasitic fungi of the organism and treatment thereof. - Google Patents
Identifying parasitic fungi of the organism and treatment thereof. Download PDFInfo
- Publication number
- ZA200309122B ZA200309122B ZA200309122A ZA200309122A ZA200309122B ZA 200309122 B ZA200309122 B ZA 200309122B ZA 200309122 A ZA200309122 A ZA 200309122A ZA 200309122 A ZA200309122 A ZA 200309122A ZA 200309122 B ZA200309122 B ZA 200309122B
- Authority
- ZA
- South Africa
- Prior art keywords
- antifungals
- approximately
- treatment
- human
- fungus
- Prior art date
Links
- 241000233866 Fungi Species 0.000 title claims description 49
- 230000003071 parasitic effect Effects 0.000 title description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 45
- 241001465754 Metazoa Species 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 23
- 230000007170 pathology Effects 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 20
- 230000002265 prevention Effects 0.000 claims description 19
- 208000034189 Sclerosis Diseases 0.000 claims description 17
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 241000123113 Phellinus igniarius Species 0.000 claims description 8
- 241000123052 Xylobolus annosus Species 0.000 claims description 8
- 230000000843 anti-fungal effect Effects 0.000 claims description 7
- 229960000988 nystatin Drugs 0.000 claims description 7
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 5
- 206010052428 Wound Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 150000004291 polyenes Chemical class 0.000 claims description 5
- 230000002784 sclerotic effect Effects 0.000 claims description 5
- 240000000925 Hericium abietis Species 0.000 claims description 4
- 244000126211 Hericium coralloides Species 0.000 claims description 4
- 235000000035 Hericium coralloides Nutrition 0.000 claims description 4
- 240000000588 Hericium erinaceus Species 0.000 claims description 4
- 241000498284 Multiclavula vernalis Species 0.000 claims description 4
- 241000543421 Peniophora piceae Species 0.000 claims description 4
- 241000032599 Peniophora pithya Species 0.000 claims description 4
- 241001635173 Rosellinia arcuata Species 0.000 claims description 4
- 241001290329 Tricholoma terreum Species 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 230000001338 necrotic effect Effects 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 3
- 208000032544 Cicatrix Diseases 0.000 claims description 3
- 206010017711 Gangrene Diseases 0.000 claims description 3
- 241000123222 Hericium Species 0.000 claims description 3
- 235000002157 Hericium abietis Nutrition 0.000 claims description 3
- 235000007328 Hericium erinaceus Nutrition 0.000 claims description 3
- 241001299714 Rosellinia necatrix Species 0.000 claims description 3
- 229960003942 amphotericin b Drugs 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 231100000241 scar Toxicity 0.000 claims description 3
- 230000037387 scars Effects 0.000 claims description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 206010011224 Cough Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- 206010051814 Eschar Diseases 0.000 claims description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 241000187747 Streptomyces Species 0.000 claims description 2
- 241000122969 Streptomyces nodosus Species 0.000 claims description 2
- 241000187310 Streptomyces noursei Species 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 231100000333 eschar Toxicity 0.000 claims description 2
- 229960004884 fluconazole Drugs 0.000 claims description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 2
- 229960004413 flucytosine Drugs 0.000 claims description 2
- 206010021198 ichthyosis Diseases 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- 229960002509 miconazole Drugs 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000001297 phlebitis Diseases 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 241000894007 species Species 0.000 description 7
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 5
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 3
- DPAGRPSAFDXQDN-UHFFFAOYSA-N 5-methoxy-8,8-dimethyl-2-phenyl-4H,8H-pyrano[2,3-h]chromen-4-one Chemical compound C=1C(=O)C=2C(OC)=CC=3OC(C)(C)C=CC=3C=2OC=1C1=CC=CC=C1 DPAGRPSAFDXQDN-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- QYCUGLCRIRALNM-DGTMTQBPSA-N (1R,3S,5R,6R,7E,11R,12S,13E,15E,17E,19E,21R,23S,24R,25S)-21-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,6,25-pentahydroxy-11,12-dimethyl-9-oxo-10,27-dioxabicyclo[21.3.1]heptacosa-7,13,15,17,19-pentaene-24-carboxylic acid Chemical compound C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)\C=C\C(=O)O[C@H](C)[C@@H](C)\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O QYCUGLCRIRALNM-DGTMTQBPSA-N 0.000 description 1
- VRTOYGUQNUQDJB-LHQLHYLDSA-N (3E,5E,7E,9E,11E,13E,16S,17S,18R,20R,22R,24S,26S,28R,30R,32R,33E,35S,36S)-36-[(2S)-butan-2-yl]-16,18,20,22,24,26,28,30,32-nonahydroxy-17,35-dimethyl-1-oxacyclohexatriaconta-3,5,7,9,11,13,33-heptaen-2-one Chemical compound CC[C@H](C)[C@@H]1OC(=O)\C=C\C=C\C=C\C=C\C=C\C=C\C[C@H](O)[C@H](C)[C@H](O)C[C@H](O)C[C@H](O)C[C@@H](O)C[C@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)\C=C\[C@@H]1C VRTOYGUQNUQDJB-LHQLHYLDSA-N 0.000 description 1
- VHMCOPURFQAZFP-BCRUFRJLSA-N (4e,6e,8e,10e,16e)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,21,23,25-tetrahydroxy-12,13-dimethyl-15-oxo-14,27-dioxabicyclo[21.3.1]heptacosa-4,6,8,10,16-pentaene-26-carboxylic acid Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1OC1/C=C/C=C/C=C/C=C/C(C)C(C)OC(=O)/C=C/CC(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 VHMCOPURFQAZFP-BCRUFRJLSA-N 0.000 description 1
- 229930186975 Arenomycin Natural products 0.000 description 1
- CYGXFHUZSVKTBA-MOAKSMKPSA-N Candidin Natural products C[C@H]1OC(=O)C[C@@H](O)C[C@@H](O)CC(=O)CC[C@@H](O)[C@H](O)CC(=O)C[C@@H](O)[C@H]([C@H](O)C[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C=CC=CC=CC=CC=CC=CC=C[C@@H](C)[C@H](O)[C@@H]1C)C(=O)O CYGXFHUZSVKTBA-MOAKSMKPSA-N 0.000 description 1
- VRTOYGUQNUQDJB-UHFFFAOYSA-N Dermostatin B Natural products CCC(C)C1OC(=O)C=CC=CC=CC=CC=CC=CCC(O)C(C)C(O)CC(O)CC(O)CC(O)CC(O)CC(O)CC(O)CC(O)C=CC1C VRTOYGUQNUQDJB-UHFFFAOYSA-N 0.000 description 1
- 241000836546 Entomocorticium sp. Species 0.000 description 1
- AGJUUQSLGVCRQA-SWOUQTJZSA-N Fungichromin Chemical compound CCCCC[C@@H](O)[C@@H]1[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)[C@@H](O)[C@H](O)\C(C)=C\C=C\C=C\C=C\C=C\[C@H](O)[C@@H](C)OC1=O AGJUUQSLGVCRQA-SWOUQTJZSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- AGJUUQSLGVCRQA-UHFFFAOYSA-N Pentamycin Natural products CCCCCC(O)C1C(O)CC(O)CC(O)CC(O)CC(O)CC(O)C(O)C(O)C(C)=CC=CC=CC=CC=CC(O)C(C)OC1=O AGJUUQSLGVCRQA-UHFFFAOYSA-N 0.000 description 1
- DXENDDMPDZMHSQ-UHFFFAOYSA-N Qingdainone Natural products C12=NC3=CC=CC=C3C(=O)N1C1=CC=CC=C1C2=C1C(=O)C2=CC=CC=C2N1 DXENDDMPDZMHSQ-UHFFFAOYSA-N 0.000 description 1
- VHMCOPURFQAZFP-UHFFFAOYSA-N Tetrin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CC(C)C(C)OC(=O)C=CCC(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 VHMCOPURFQAZFP-UHFFFAOYSA-N 0.000 description 1
- QYCUGLCRIRALNM-UHFFFAOYSA-N Tetrin B Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CC(C)C(C)OC(=O)C=CC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QYCUGLCRIRALNM-UHFFFAOYSA-N 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- LSYAYTGVPHMMBZ-YPCSGYANSA-N dermostatin a Chemical compound CC(C)[C@@H]1OC(=O)\C=C\C=C\C=C\C=C\C=C\C=C\C[C@H](O)[C@H](C)[C@H](O)C[C@H](O)C[C@H](O)C[C@@H](O)C[C@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)\C=C\[C@@H]1C LSYAYTGVPHMMBZ-YPCSGYANSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960000339 pentamycin Drugs 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56961—Plant cells or fungi
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0106775A FR2825024B1 (fr) | 2001-05-23 | 2001-05-23 | Identification de champignons parasites de l'organisme, et leur traitement |
| FR0109203A FR2827173B3 (fr) | 2001-07-11 | 2001-07-11 | Identification de champignons parasites de l'organisme, et leur traitement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200309122B true ZA200309122B (en) | 2004-11-24 |
Family
ID=26213022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200309122A ZA200309122B (en) | 2001-05-23 | 2003-11-24 | Identifying parasitic fungi of the organism and treatment thereof. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20040198633A1 (sk) |
| EP (1) | EP1389120B1 (sk) |
| KR (1) | KR20040018377A (sk) |
| CN (1) | CN1518451A (sk) |
| BG (1) | BG66299B1 (sk) |
| BR (1) | BR0209869A (sk) |
| CA (1) | CA2448045A1 (sk) |
| CZ (1) | CZ20033145A3 (sk) |
| EE (1) | EE200300572A (sk) |
| HU (1) | HUP0400035A2 (sk) |
| IL (1) | IL158967A0 (sk) |
| NO (1) | NO20035188D0 (sk) |
| NZ (1) | NZ529764A (sk) |
| PL (1) | PL367700A1 (sk) |
| RU (1) | RU2003136777A (sk) |
| SK (1) | SK14372003A3 (sk) |
| WO (1) | WO2002094287A2 (sk) |
| ZA (1) | ZA200309122B (sk) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9314524B2 (en) * | 2007-12-31 | 2016-04-19 | Calla Therapeutics Llc | Topical formulations of Flucytosine |
| CN103044376A (zh) * | 2012-12-15 | 2013-04-17 | 青岛农业大学 | 桑黄菌中吡喃酮的分离技术 |
| CN116515641B (zh) * | 2023-04-26 | 2023-09-29 | 吉林农业大学 | 一株珊瑚状猴头菌及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2786781A (en) * | 1954-11-04 | 1957-03-26 | Olin Mathieson | Process of recovering nystatin |
| US2908611A (en) * | 1954-12-28 | 1959-10-13 | Olin Mathieson | Amphotericin b, its production, and its salts |
| US3714348A (en) * | 1970-12-02 | 1973-01-30 | Schmid Inc Julius | Method for controlling absorption of cholesterol |
| US4025620A (en) * | 1975-10-22 | 1977-05-24 | Leo Pharmaceutical Products Ltd., A/S | Treatment of canine otitis and composition therefor |
| US4491588A (en) * | 1982-03-31 | 1985-01-01 | University Of Tennessee Research Corporation | Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics |
| GB9320744D0 (en) * | 1992-11-04 | 1993-12-01 | Zeneca Ltd | Oxa and thiadiazole derivatives |
| US5358959A (en) * | 1993-02-18 | 1994-10-25 | President And Fellows Of Harvard University | Methods for treating arteriosclerosis |
| EP0771205A2 (de) * | 1994-06-28 | 1997-05-07 | Dr. Zerle Gmbh | Neue klinische anwendungen von polyen-makroliden |
| US5914239A (en) * | 1995-11-15 | 1999-06-22 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Diagnosis of fungal infections, and a chitin-binding lectin useful in such diagnoses |
| WO2001014592A2 (en) * | 1999-08-25 | 2001-03-01 | Clarity Biosciences, Inc. | Identifying organisms by detecting intronic nucleic acid or encoded proteins |
-
2002
- 2002-05-23 US US10/478,508 patent/US20040198633A1/en not_active Abandoned
- 2002-05-23 KR KR10-2003-7015339A patent/KR20040018377A/ko not_active Application Discontinuation
- 2002-05-23 NZ NZ529764A patent/NZ529764A/en unknown
- 2002-05-23 CZ CZ20033145A patent/CZ20033145A3/cs unknown
- 2002-05-23 EP EP02732883A patent/EP1389120B1/fr not_active Expired - Lifetime
- 2002-05-23 SK SK1437-2003A patent/SK14372003A3/sk unknown
- 2002-05-23 IL IL15896702A patent/IL158967A0/xx unknown
- 2002-05-23 CA CA002448045A patent/CA2448045A1/fr not_active Abandoned
- 2002-05-23 RU RU2003136777/15A patent/RU2003136777A/ru not_active Application Discontinuation
- 2002-05-23 WO PCT/FR2002/001739 patent/WO2002094287A2/fr not_active Application Discontinuation
- 2002-05-23 PL PL02367700A patent/PL367700A1/xx not_active Application Discontinuation
- 2002-05-23 EE EEP200300572A patent/EE200300572A/xx unknown
- 2002-05-23 CN CNA02812510XA patent/CN1518451A/zh active Pending
- 2002-05-23 HU HU0400035A patent/HUP0400035A2/hu unknown
- 2002-05-23 BR BR0209869-5A patent/BR0209869A/pt not_active IP Right Cessation
-
2003
- 2003-11-21 BG BG108375A patent/BG66299B1/bg unknown
- 2003-11-21 NO NO20035188A patent/NO20035188D0/no not_active Application Discontinuation
- 2003-11-24 ZA ZA200309122A patent/ZA200309122B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002094287A3 (fr) | 2003-09-25 |
| CZ20033145A3 (cs) | 2004-10-13 |
| EE200300572A (et) | 2004-02-16 |
| NZ529764A (en) | 2005-08-26 |
| PL367700A1 (en) | 2005-03-07 |
| BR0209869A (pt) | 2004-04-20 |
| CA2448045A1 (fr) | 2002-11-28 |
| IL158967A0 (en) | 2004-05-12 |
| BG108375A (bg) | 2005-01-31 |
| EP1389120A2 (fr) | 2004-02-18 |
| WO2002094287A2 (fr) | 2002-11-28 |
| EP1389120B1 (fr) | 2012-08-01 |
| HUP0400035A2 (hu) | 2004-04-28 |
| CN1518451A (zh) | 2004-08-04 |
| SK14372003A3 (sk) | 2004-05-04 |
| RU2003136777A (ru) | 2005-04-10 |
| KR20040018377A (ko) | 2004-03-03 |
| NO20035188D0 (no) | 2003-11-21 |
| BG66299B1 (bg) | 2013-03-29 |
| US20040198633A1 (en) | 2004-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Masuda et al. | Maitake β-glucan enhances therapeutic effect and reduces myelosupression and nephrotoxicity of cisplatin in mice | |
| US7807622B2 (en) | Composition and use of phyto-percolate for treatment of disease | |
| RU2410100C2 (ru) | Фармацевтическая композиция ингибитора протонной помпы и пребиотика для лечения язвенных поражений желудка и 12-перстной кишки | |
| JP2019031501A (ja) | メタン細菌に起因または関連する疾患および状態を診断、選択、および処置する方法 | |
| KR101399621B1 (ko) | 클로스트리듐 디피실리 관련 설사의 치료 방법 | |
| US20200297780A1 (en) | Anti-inflammatory compositions, methods and uses thereof | |
| JPH09511220A (ja) | バクテリアによって誘発される炎症性疾患の治療 | |
| US8586053B2 (en) | Composition and use of phyto-percolate for treatment of disease | |
| ZA200309122B (en) | Identifying parasitic fungi of the organism and treatment thereof. | |
| JP3995733B2 (ja) | 免疫賦活組成物 | |
| JP2021526526A (ja) | 細菌株を含む組成物 | |
| KR20130136434A (ko) | 발효된 대두 추출물의 프리바이오틱 조성물 제조를 위한 용도 | |
| FR2827173A1 (fr) | Identification de champignons parasites de l'organisme, et leur traitement | |
| CA3093373A1 (en) | N-acylated hyaluronic acid for hyperuricemia and gouty arthritis | |
| WO2018213766A1 (en) | Compositions and methods for improving cognition | |
| US20230404969A1 (en) | Compositions and method for effective management of peritonitis | |
| FR2825024A1 (fr) | Identification de champignons parasites de l'organisme, et leur traitement | |
| CN117838736B (zh) | 凝结芽孢杆菌ja845在制备预防和/或治疗抗动脉粥样硬化药物中的应用 | |
| WO2000024402A1 (fr) | Utilisation d'antifongiques dans le traitement des scleroses | |
| CN109771446B (zh) | 唾液链球菌k12在制备预防和/或治疗自身免疫性疾病的药物中的应用 | |
| WO2022178209A1 (en) | Compositions and methods for treating metabolic diseases and disorders using christensenellaceae bacteria | |
| Vanlancker | The impact of chemotherapy on the host microbiota in the context of oral and gastrointestinal mucositis | |
| EP1691802B1 (en) | Methods for the amelioration of environmental oxidant stress and the regulation of beneficial genes | |
| CN115381818A (zh) | 一种促进细胞自噬降解功能的方法及应用 |